X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TNG348 is a novel selective inhibitor of USP1 (ubiquitin-specific protease 1) which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ (homologous recombination deficient) cancers.
Lead Product(s): TNG348,Olaparib
Therapeutic Area: Oncology Product Name: TNG348
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers.
Lead Product(s): TNG348
Therapeutic Area: Oncology Product Name: TNG348
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Medivir
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), is being developed for the treatment of BRCA1/2 mutant and other HRD+ (homologous recombination deficient) cancers.
Lead Product(s): TNG348,Olaparib
Therapeutic Area: Oncology Product Name: TNG348
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
The proceeds are expected to enable rapid expansion across multiple tumor types for the TNG908 and TNG462 PRMT5 programs, as well as maintain funding through proof-of-concept for each of its clinical-stage programs as the Company awaits clinical data.
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nextech
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 10, 2023
Details:
TNG260 is a first-in-class inhibitor of the CoREST complex (Co-repressor of Repressor Element-1 Silencing Transcription) being developed in combination with pembrolizumab in patients with STK11-mutant cancers.
Lead Product(s): TNG260,Pembrolizumab
Therapeutic Area: Oncology Product Name: TNG260
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor, being investigated for the treatment of patients with MTAP-deleted solid tumors and is previously granted Fast Track designation by the U.S. Food and Drug Administration.
Lead Product(s): TNG462
Therapeutic Area: Oncology Product Name: TNG462
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
TNG260 is a first-in-class inhibitor of the CoREST complex ( Co-repressor of Repressor Element-1 Silencing Transcription), being investingated for the treatment of STK11-mutant cancers.
Lead Product(s): TNG260
Therapeutic Area: Oncology Product Name: TNG260
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
TNG908 is administered orally, a selective PRMT5 inhibitor that drives tumor regression, it is being developed for the treament of MTAP-deleted glioblastoma (GBM).
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
In preclinical studies, TNG462 is 45X selective for MTAP-deletions (3-fold greater than TNG908) and 20 times more potent than TNG908, which may provide a wider therapeutic index and stronger target inhibition than TNG908.
Lead Product(s): TNG462
Therapeutic Area: Oncology Product Name: TNG462
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
TNG908 is an investigational PRMT5 inhibitor with a novel MTA-cooperative binding mechanism designed to leverage the synthetic lethal interaction between PRMT5 inhibition and MTAP deletion.
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
